Basel pharmacy trial reports small symptom declines after one year

Adults receiving cannabis through Basel’s Weed Care pharmacy trial showed small average reductions in depression, anxiety and problematic use over one year. The participating medical institution reported the findings on 14 September 2026. Cannabis-use days increased slightly, while the amount used on a consumption day stayed similar.^[1]

A pharmacy model for existing users

Weed Care examined regulated supply through pharmacies, without a profit motive and with advice when cannabis was dispensed. It followed adults who already used cannabis regularly. This gave researchers a way to observe a model in which controlled products and contact with pharmacists accompanied legal access.^[1]

The study’s abstract describes limits of 20% THC and ten grams of THC per month. Its 374 participants had an average age of 35.8, and 81% were men. Those details matter when considering whom the findings describe: this was a particular group of existing consumers in Basel.^[2]

Small changes across the year

The average declines in depression, anxiety and problematic-use scores were statistically significant but small. Participants with higher problematic-use scores at the outset showed a larger reduction. The proportion exceeding clinical thresholds did not change significantly, even though mean symptom scores improved.^[2]

The institution reported unchanged psychosis-like symptoms and unchanged amounts per consumption day, alongside the slight increase in consumption days. Frequency and amount per occasion therefore tell different parts of the story.^[1]

Why the comparison matters

After six months, both original study groups had access to pharmacy cannabis. The one-year analysis consequently follows changes within participants without a continuing untreated comparison. It cannot establish that pharmacy access caused the changes in symptoms or consumption.^[1][2]

That limitation is central to interpreting the result. The findings describe how this cohort developed while receiving regulated supply; they do not provide a controlled estimate of the model’s effect on mental health.^[2]

One study within Switzerland’s wider trials

The 2021 enabling law lets Switzerland test non-medical supply in projects limited by place and duration. Federal rules require controlled product quality, trained sales staff, protection of minors and a ban on advertising. Each project chooses its particular research questions.^[3]

Basel’s follow-up contributes one piece of that evidence. The broader programme is intended to inform future regulation by examining health, consumption, social circumstances and illegal markets. The Swiss profile follows the developing evidence alongside the rules that govern access today.^[3]